← SynDRA
VALRUBICIN
SynDRA canonical compound SYN0021757 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TOP2A |
|---|
| Mechanism of action | Topoisomerase inhibitor |
|---|
| Indication | bladder cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- DNA inhibitor
- topoisomerase inhibitor
- TOP2A INHIBITOR
- DNA topoisomerase II alpha inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- ABCC2
- ABCC3
- ABCC4
- HDAC6
- TDP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- ATAD5
- GCR
- IFNB1
- IFNG
- KSYK
- NSD2
- PARP1
- SYK
- TP53
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
ATC classes
- L01D · CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Cross-references
Synonyms
- VALSTAR PRESERVATIVE FREE
- Valstar
- N-Trifluoroacetyladriamycin 14-valerate
- valstar
- N-Trifluoroacetyldoxorubicin 14-valerate
- AD-32
- Valrubicine
- Valrubicina
- NSC-246131
- Valstar preservative free
- Valrubicin [USAN]
- Valstar Preservative Free
- AD 32
- Antibiotic AD 32
- Valstar (TN)
- N-Trifluoroacetyladriamycin-14-valerate
- Trifluoroacetyladriamycin-14-valerate
- Valrubicin (USP/INN)
- Adriamycin, trifluoroacetyl-, 14-valerate
- NSC 246131
- Valrubicin (AD-32)
- 2C6NUM6878
- Valtaxin
- UNII-2C6NUM6878
- Valrubicin [USAN:USP:INN]
- AD32
- NSC246131
- HSDB 7288
- NCGC00164738-01
- VALRUBICIN [MI]
- VALRUBICIN [INN]
- VALRUBICIN [HSDB]
- VALRUBICIN [VANDF]
- VALRUBICIN [MART.]
- VALRUBICIN [USP-RS]
- VALRUBICIN [WHO-DD]
- SCHEMBL12824
Reported adverse events
- Asthenia
- Cyst
- Cystitis
- Dizziness
- Dysuria
- Flatulence
- Headache
- Malaise
- Myalgia
- Nausea
- Nocturia
- Pruritus
Look up VALRUBICIN in the interactive SynDRA portal →